Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH)
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms JPMS-PAH
- Sponsors Bayer
- 10 Jun 2017 Biomarkers information updated
- 16 Jul 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
- 15 Jun 2015 Planned initiation date changed from 1 May 2015 to 1 Jun 2015, according to to ClinicalTrials.gov record.